JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M413748200 on June 24, 2005

J. Biol. Chem., Vol. 280, Issue 33, 29921-29928, August 19, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/33/29921    most recent
M413748200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vitale, N.
Right arrow Articles by Chasserot-Golaz, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vitale, N.
Right arrow Articles by Chasserot-Golaz, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Small GTPase RalA Controls Exocytosis of Large Dense Core Secretory Granules by Interacting with ARF6-dependent Phospholipase D1*

Nicolas Vitale{ddagger}, Jacques Mawet{ddagger}, Jacques Camonis§, Romano Regazzi¶, Marie-France Bader{ddagger}||, and Sylvette Chasserot-Golaz{ddagger}

From the {ddagger}Centre National de la Recherche Scientifique, Unité Propre de Recherche 2356 Neurotransmission and Sécrétion Neuroendocrine, 5 Rue Blaise Pascal, 67084 Strasbourg France, §Institut Curie, Institut National de la Santé et de la Recherche Médicale U-528, 75248 Paris, France, and Institut de Biologie Cellulaire et de Morphologie, University of Lausanne, 1005 Lausanne, Switzerland

Received for publication, December 7, 2004 , and in revised form, June 24, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
RalA and RalB constitute a family of highly similar Ras-related GTPases widely distributed in different tissues. Recently, active forms of Ral proteins have been shown to bind to the exocyst complex, implicating them in the regulation of cellular secretion. Since RalA is present on the plasma membrane in neuroendocrine chromaffin and PC12 cells, we investigated the potential role of RalA in calcium-regulated exocytotic secretion. We show here that endogenous RalA is activated during exocytosis. Expression of the constitutively active RalA (G23V) mutant enhances secretagogue-evoked secretion from PC12 cells. Conversely, expression of the constitutively inactive GDP-bound RalA (G26A) or silencing of the RalA gene by RNA interference led to a strong impairment of the exocytotic response. RalA was found to co-localize with phospholipase D1 (PLD1) at the plasma membrane in PC12 cells. We demonstrate that cell stimulation triggers a direct interaction between RalA and ARF6-activated PLD1. Moreover, reduction of endogenous RalA expression level interfered with the activation of PLD1 observed in secretagogue-stimulated cells. Finally, using various RalA mutants selectively impaired in their ability to activate downstream effectors, we show that PLD1 activation is essential for the activation of secretion by GTP-loaded RalA. Together, these results provide evidence that RalA is a positive regulator of calcium-evoked exocytosis of large dense core secretory granules and suggest that stimulation of PLD1 and consequent changes in plasma membrane phospholipid composition is the major function RalA undertakes in calcium-regulated exocytosis.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
RalA and RalB constitute a family of proteins within the Ras branch of monomeric GTPases (1). They are highly similar, sharing over 85% amino acid sequence identity, and display a widespread overlapping tissue distribution (2). Like most Ras family GTPases, Ral proteins have been implicated in the regulation of various cell biological processes, including oncogenic transformation, endocytosis, and actin-cytoskeleton dynamics (3).

Ral proteins have the potential to be activated by many different extracellular signals. One of the best known Ral-activating pathways is via Ral-specific guanine nucleotide exchange factors that become activated by binding GTP-bound Ras in response to many types of upstream signals, including almost all tyrosine kinase receptors and several G-protein-linked receptors (3-5). However, Ras-independent mechanisms of Ral activation occur as well. For instance, in platelets and in fibroblasts, elevation of intracellular calcium levels directly induces Ral activation without a contribution of Ras (6). The small GTPase Rap has been also identified as a Ral activator under some conditions (7).

Ral interacts with several protein effectors through two protein-protein interaction sites. The first binds phospholipase D1 (PLD1)1 via an N-terminal 11-amino acid sequence. Ral weakly stimulates PLD1 activity but operates synergistically with small GTPases of the ARF family (8, 9). The second is an effector-binding loop, which mediates interaction with Ral-binding protein 1 (RalBP1, also known as RLIP76) and filamin. RalBP1 was the first Ral effector to be identified and was originally distinguished by its GTPase-activating protein domain, which has the potential to regulate Rac and Cdc42 GTPases negatively (10-12). Filamin is an actin cross-linking protein that mediates filopodia formation (13). More recently, Ral was found associated in a GTP-dependent manner with the mammalian exocyst (14-16), a multiprotein complex that functions in polarized cells in membrane delivery to specific domains of the plasma membrane (17-19).

Several evidence support the idea that Ral proteins are intimately linked to vesicular trafficking events at the plasma membrane. First, RalBP1 regulates recycling of epidermal growth factor and insulin receptors by interacting with epsin homology domain proteins involved in endocytosis (20-22). RalBP1 also binds to the AP2 adaptor complex (23), which plays a key role in clathin-mediated endocytosis. Second, Ral has been shown to participate in receptor-mediated endocytosis through a process that involves PLD (24). Third, activated Ral proteins have been implicated in the targeting of Golgi-derived vesicles to the basolateral membrane in epithelial cells (15, 25). This possibility arose from the discovery that two subunits of the exocyst complex are downstream binding partners of active RalA and RalB (14-16, 26). In budding yeast, the exocyst directs targeting of secretory vesicles to sites of rapid membrane growth (17). Consistent with a function in membrane addition, the analogous mammalian complex has been found at the tight junctions of epithelial cells, where it has been implicated in basolateral secretion (15, 27) and in axonal growth cones of developing neurons (28). Thus, by promoting assembly of the exocyst complex (26), Ral proteins have been proposed to regulate exocyst-mediated vesicle delivery to appropriate fusion sites at the plasma membrane.

Release of hormones and neurotransmitters occurs through a specialized form of exocytosis that is tightly regulated in time and space by extracellular signals and cytosolic calcium levels. The presence of Ral proteins at high levels on synaptic vesicles (29, 30) and secretory granules in platelets (31) has led to the speculation that Ral may play a role in calcium-regulated exocytosis. Hence, a role for Ral in a regulatory aspect of neurotransmitter release has been identified through the analysis of neuronal tissue from transgenic mice expressing a dominant inhibitory form of RalA (32). Release of glutamate from isolated synaptic endings after depolarization was found normal in the transgenic mice, but protein kinase C-mediated enhancement of glutamate secretion was suppressed. This suggested the participation of Ral in some forms of synaptic plasticity linked to the recruitment of synaptic vesicles but not in neuronal exocytosis per se. In neuroendocrine PC12 cells, Ral proteins have been implicated in exocytosis by regulating the assembly of exocyst complexes (15). However, a recent report by Wang et al. (33) indicates that RalA plays its exocyst-mediated function in GTP-dependent but not in calcium-dependent exocytosis. Thus, the participation and precise function of Ral proteins in calcium-regulated secretion remains unclear.

In chromaffin cells, we previously reported the presence of RalA on the plasma membrane, whereas RalB resided on some intracellular vesicles that were distinct from catecholamine-containing secretory granules (34). This observation led us to further explore the role of RalA in the calcium-regulated exocytotic process. In the present paper, we show that RalA is a positive regulator of dense core granule exocytosis. Moreover, we obtained a series of results indicating that ARF6-regulated PLD1, present on the plasma membrane and implicated in the late stages of exocytosis (35, 36), participates in the downstream pathway by which RalA promotes calcium-regulated exocytosis.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Plasmids and Small Interference RNA (siRNA)—RalA wild type and variants were as previously described (15) and were expressed in PC12 cells using pRK5. The sequence encoding the Ral-binding domain of RalBP1/RLIP76 (amino acids 403-499) was inserted as a BamHI-EcoRI fragment into pRK5-Myc. Recombinant HA-ARF6 proteins were expressed in PC12 cells as described (36). The PLD1-nonresponsive HA-ARF6(N48I) mutant was generated by site-directed mutagenesis. Its nucleotide exchange activity, activation by ARNO, and inactivation by an ARF6-GAP; intracellular distribution when expressed in PC12 cells; and in vitro effect on PLD1 activity were characterized and previously described (36).

Rat RalA cDNA fragments encoding the 19-nucleotide siRNA sequence (AAGGCAGGTTTCTGTAGAA) derived from the target transcript and separated from its reverse 19-nucleotide complement by a short spacer were annealed and cloned in front of the H1-RNA promoter from the pSuper vector (37). The specificity of the sequence was verified by BLAST search against the gene data bank. For mammalian expression vectors encoding both small hairpin RNAs (shRNAs) and growth hormone (GH), a cassette containing the H1-RNA promoter and the silencing sequence was amplified by PCR as described previously (38) and subcloned within the HindIII and XbaI sites of pXGH5 (Nichols Institute, San Juan Capistrano, CA). The empty vector with no siRNA sequence was named pGHsuper. To estimate the silencing effect, the RalA-shRNA plasmid was electroporated (260 V, 1050 microfarads, for 17 ms) in 107 PC12 cells, and 72 h post-transfection, cells were used for Western blot and immunofluorescence experiments. The transfection efficiency under these conditions was measured by counting GH-positive cells and was found to be 53% (432 of 815) for pGHsuper and 55% (541 of 983) for RalA-shRNA.

Chromaffin Cell Culture and Subcellular Fractionation—Chromaffin cells were isolated from fresh bovine adrenal glands by retrograde perfusion with collagenase, purified on self-generating Percoll gradients, and maintained in culture as previously described (39). For immunocytochemistry, cells were cultured on fibronectin-coated glass coverslips at a density of 2.5 x 105 cells/12-mm plate. In some experiments, cells were homogenized in 10 mM imidazole, pH 7.4, containing protease inhibitors and then centrifuged at 200,000 x g for 45 min (40). The supernatant was saved (cytosol), and the pellet was resuspended in 10 mM imidazole, pH 7.4, 75 mM KCl, 2 mM MgCl2, 1 mM NaN3, and 0.5% Triton X-100 containing protease inhibitors. After centrifugation at 200,000 x g for 45 min, the supernatant (Triton X-100-soluble fraction) and the pellet (Triton X-100-insoluble fraction) were saved and solubilized in sample buffer for gel electrophoresis (40).

Culture, Transfection, and Growth Hormone (GH) Release from PC12 Cells—PC12 cells were grown in Dulbecco's modified Eagle's medium supplemented with glucose (4500 mg/liter) and containing 30 mM NaHCO3, 5% fetal bovine serum, 10% horse serum, and 100 units/ml penicillin/streptomycin. Mammalian expression vectors were introduced into PC12 cells together with the GH plasmid pXGH5 (6-well dishes, 80% confluent, 4 µg/well of each plasmid) using GenePorter (Gene Therapy Systems) according to the manufacturer's instructions. After 5 h of incubation at 37 °C, 2 ml of culture medium containing fetal bovine serum, horse serum, and antibiotics was added.

GH release experiments were performed 48 h after transfection. PC12 cells were washed twice with Locke's solution and then incubated for 10 min with calcium-free Locke's solution (basal release) or stimulated with an elevated K+ solution (Locke's containing 59 mM KCl and 85 mM NaCl). The supernatant was collected, and the cells were harvested by scraping in 10 mM phosphate-buffered saline. The amounts of GH secreted into the medium and retained in the cells were measured using a radioimmunoassay kit (Nichols Institute). The amount of GH secretion is expressed as a percentage of total GH present in the cells before stimulation. GH release experiments were performed on at least three different cell cultures. In the figures that are representative of a typical experiment, data are given as the mean of triplicate determinations performed on the same cell preparation ± S.E.

Assay for PLD Activity—Transfected PC12 cells were washed twice with Locke's solution and then incubated for 10 min with calcium-free Locke's solution (basal release) or stimulated with an elevated K+ solution (Locke's containing 59 mM KCl and 85 mM NaCl). Medium was replaced with 100 µl of ice-cold Tris (50 mM, pH 8.0), and cells were broken by three freeze and thaw cycles. Samples were collected, mixed with an equal amount of the Amplex Red reaction buffer (Amplex Red Phospholipase D assay kit, Molecular Probes, Inc., Eugene, OR), and the PLD activity was estimated after a 1-h incubation at 37 °C with a Mithras (Berthold) fluorimeter. A standard curve was performed with purified PLD from Streptomyces chromofuscus (Sigma). In Fig. 4D, data are given as the mean of six determinations performed on the same cell preparation ± S.E. Similar results were obtained on four different cell preparations.

Antibodies and Immunofluorescence—The following antibodies were used: monoclonal anti-RalA and rabbit polyclonal anti-RalB (Transduction Laboratories, Lexington, KY); polyclonal anti-PLD1 raised in rabbits against the N-terminal domain of PLD1 (QCB, BIOSOURCE International, France); monoclonal anti-SNAP-25 antibodies (Sternberger Monoclonals Inc., Lutherville, MD); monoclonal anti-HA antibodies (Babco, Richmond, CA); monoclonal anti-Myc antibodies (Novocostra Laboratories); polyclonal anti-GH (Dr. A. F. Parlow, NIDDK, National Institutes of Health, Bethesda, MD); Alexa-488-anti-mouse and Alexa-555-anti-rabbit (Molecular Probes). Rabbit polyclonal anti-chromogranin A antibodies were prepared in our laboratory (41). For immunocytochemistry, chromaffin or PC12 cells on coated glass coverslips were fixed and immunostained as described previously (35, 40). Stained cells were visualized with a Zeiss confocal microscope LSM 510. Using the Zeiss CLSM instrument software 3.2, the amount of RalA labeling was measured and expressed as the average fluorescence intensity multiplied by the corresponding surface area and divided by the total surface of each cell. This allows a quantitative cell-to-cell comparison of the RalA immunoreactivity detected in cells.

Immunoprecipitation—PC12 cells transfected with pXS-HA-ARF6 or pXS-HA-ARF6(N48I) were maintained in Locke's solution or stimulated with 59 mM K+. Cells were then lysed, and ARF6 proteins were immunoprecipitated with anti-HA antibodies and protein A-Sepharose beads as described (36).

GTP-bound RalA was specifically pulled down using the Myc-RBD (Ral-binding domain) of Ral-binding protein 1 (RalBP1). Therefore, PC12 cells expressing Myc-RBD were maintained under resting conditions or stimulated for various periods of time with 59 mM K+. Cells were then lysed in ice-cold lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 20 mM MgCl2, 5 mM EDTA, 1% Nonidet P-40, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, and mammalian protease inhibitors) (Sigma). Lysates were clarified by centrifugation and Myc-tagged proteins were immunoprecipitated from the supernatant of each sample using agarose-coupled mouse anti-Myc IgG. Precipitated proteins were resolved on 12% polyacrylamide-SDS gels and immunoblotted with anti-Myc (1:500) and anti-RalA (1:1000) antibodies. Blots were processed using the "Western-Light Plus" chemiluminescent detection system (Tropix, Bedford, MA).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Intracellular Distribution of RalA in Resting and Stimulated Chromaffin and PC12 Cells—We investigated the intracellular distribution of native RalA in cultured chromaffin cells by immunofluorescence and confocal microscopy. As illustrated in Fig. 1, RalA was restricted to the cell periphery. Double labeling with antibodies against the plasma membrane marker SNAP25 or against the chromaffin granule protein chromogranin A (CGA) indicated its association with the plasma membrane but not with the membrane of secretory granules (Fig. 1A). Endogenous RalA was similarly present at the plasma membrane in the chromaffin cell tumor derivatives, PC12 cells (see Fig. 6A). Next, we compared the distribution of RalA in resting and secretagogue-stimulated cells. Stimulation of chromaffin cells with nicotine (Fig. 1B) or stimulation of PC12 cells with a depolarizing concentration of potassium (59 mM K+) (Fig. 6A) reduced the level of peripheral RalA immunoreactivity by ~85% without apparently increasing it in the cytosol or in other intracellular compartments. One possible explanation for this observation is that the monoclonal antibody recognized an epitope that was masked in stimulated cells due to the formation of a RalA-protein complex.

Subcellular fractionation experiments were performed on chromaffin cell homogenates to separate the cytosol, the Triton X-100-soluble fraction representing the membrane-bound compartment, and the Triton X-100-insoluble fraction representing the cytoskeleton and some detergent-resistant lipid microdomains. RalA was primarily detected in the Triton X-100-soluble fraction (Fig. 1C), suggesting that its presence in the cell periphery was most likely due to a binding to the plasma membrane rather than to an association with the actin filaments concentrated in the subplasmalemmal region. The distribution of RalA in the fractions prepared from nicotine-stimulated cells remained largely unchanged except for a slight increase detected in the Triton X-100-insoluble fraction (Fig. 1C). Taken together, these results suggest that RalA resides at the plasma membrane in resting cells. Since the protein was hardly detectable in stimulated cells, we concluded that RalA might be engaged in a putative complex with a regulator/effector protein formed in response to secretagogue-evoked stimulation.

Secretagogue-evoked Stimulation Activates RalA in PC12 Cells—To probe the role of RalA in the control of dense core granule exocytosis, we first investigated whether RalA might be activated in response to a secretagogue that triggers exocytosis. Therefore, PC12 cells were maintained under resting conditions or stimulated for various periods of time with 59 mMK+, and RalA activation was assessed using the Ral-binding domain of RalBP1 (Myc-RBD) as a bait to trap the endogenous GTPase in its GTP-bound form (Fig. 2). We found that the amount of GTP-bound RalA is relatively low in resting cells. However, 2-10 min of stimulation with 59 mM K+ increased the level of cellular RalA-GTP by 3-10-fold, respectively (Fig. 2, A and B). Importantly, RalA-GTP rapidly decreased to basal levels as cells returned to the resting condition, revealing a tight coupling between membrane depolarization and RalA activation. Since the immediate consequence of membrane depolarization is calcium influx and secretion, these findings indicate that RalA activation is triggered by a rise in cytosolic calcium and thereby accompanies the exocytotic process.



View larger version (25K):
[in this window]
[in a new window]
  		FIG. 1.
Localization of endogenous RalA in chromaffin cells. A, confocal immunofluorescent images obtained by labeling resting chromaffin cells with anti-RalA antibodies visualized with Alexa-555-conjugated secondary antibodies and with anti-SNAP25 or anti-chromogranin A (CGA) antibodies visualized with Alexa-488-conjugated secondary antibodies. Confocal images in the green (SNAP25/CGA) or red (RalA) channels were recorded simultaneously in the same optical section by a double exposure procedure. In the merge images, the yellow-orange staining indicates the areas of co-localization. Bars, 5 µm. B, immunocytochemical distribution of RalA in nicotine-stimulated chromaffin cells. Cells were stimulated for 10 min with 10 µM nicotine in Locke's solution, fixed, and stained as in A. The histogram represents a semiquantitative analysis of the amount of RalA immunoreactivity found in resting (R) and nicotine-stimulated (S) cells (results ± S.E., n = 14 cells). Bar, 5 µm. C, immunodetection of RalA in subcellular fractions prepared from resting and stimulated cells. Cells were maintained in Locke's solution (R) or stimulated for 10 min with 10 µM nicotine (S) and then processed to separate the cytosol (Cy), the Triton X-100-soluble (TS), and the Triton X-100-insoluble (TIS) fractions. Proteins were separated by gel electrophoresis and transferred to nitrocellulose sheets, and blots were incubated with anti-RalA antibodies. Immunolabeled bands were revealed with the ECL detection system. The density of the immunoreactive RalA bands was quantified using the Fuji {beta} phosphor imager, expressed as arbitrary units (A.U.), and given as the mean values obtained from three independent fractionations ± S.E.

 
RalA Regulates Exocytosis of Large Dense Core Secretory Granules in PC12 Cells—To establish that RalA plays a role in exocytosis, we first examined the effect of expressing the Ral-binding domain of RalBP1 (Myc-RBD) in PC12 cells using growth hormone as a reporter for exocytosis (35). This protein fragment specifically binds to activated Ral-GTP and thereby interferes through competitive association with the ability of endogenous Ral proteins to interact with and stimulate effector molecules. As shown in Fig. 3, expression of Myc-RBD did not affect cell viability or GH expression level as judged by the GH immunodetected on nitrocellulose or by the total cellular GH content measured by radioimmunoassay. However, expression of Myc-RBD strongly reduced the K+-evoked GH secretion (~60% inhibition), whereas expression of RalBP1 deleted of the RBD and unable to bind to GTP-loaded Ral was ineffective. These results suggest that interactions of endogenous Ral-GTP proteins with downstream effectors are required for exocytosis.



View larger version (28K):
[in this window]
[in a new window]
  		FIG. 2.
GTP-loaded RalA pull-down assay in resting and stimulated PC12 cells. A, PC12 cells transfected with pRK-Myc-RBD were stimulated for the indicated periods of time with 59 mM K+ and/or maintained in Locke's solution for 10 min. Cells were then immediately lysed by the addition of ice-cold lysis buffer, and the lysate was used for immunoprecipitation of Myc-RBD using an anti-Myc antibody. Pulled-down Myc-RBD and GTP-loaded RalA were analyzed by gel electrophoresis and Western blots. Top panel, Western blot performed with anti-Myc antibody, revealing the amount of Myc-RBD present in each sample. Lower panel, RalA-GTP levels co-precipitated with Myc-RBD and revealed with an anti-RalA antibody. B, semi-quantitative analysis of RalA activation upon cell stimulation. Values obtained by scanning densitometry analysis are expressed as arbitrary units (A.U.) and given as the mean of values obtained from three independent experiments performed on different cell preparations ± S.E.

 
To directly address the role of RalA in PC12 cell exocytosis, we selectively inhibited native levels of RalA by taking advantage of the possibilities offered by the RNA interference process. RNA interference is based on short double-stranded RNA molecules called siRNAs that trigger specific silencing of gene expression in a sequence-specific manner (42, 43). siRNAs can be generated in mammalian cells using plasmids that direct the transcription of short hairpin RNAs (37). We engineered a plasmid to express simultaneously GH and siRNAs targeted against the sequence of RalA. Transient expression of the RalA silencer in PC12 cells selectively reduced the level of RalA but did not affect the expression of RalB, as assessed by immunodetection on nitrocellulose sheets (Fig. 4A). Densitometry scanning of the films from three independent experiments revealed that the total level of RalA in the cell culture was decreased by 40 ± 5%, whereas the RalB level was not significantly affected (97 ± 5% of the level found in control cells). Taking into account that 55% of the cells were transfected (see "Materials and Methods"), this result indicates that on average the level of endogenous RalA was reduced by 77% in cells expressing GH and the RalA siRNA. The silencing effect was also verified by immunocytochemistry. Transfected cells identified by the expression of GH were found to contain significantly lower levels of RalA immunoreactivity in the cell periphery (Fig. 4B). The involvement of RalA in exocytosis was then estimated by measuring basal and K+-evoked secretion of GH. Expression of RalA siRNAs did not reduce the expression level of GH (Fig. 4A); nor did it affect the distribution of GH in secretory granules (Fig. 4B). Selective knock down of RalA by siRNA also did not modify basal secretion, but it resulted in a significant decrease (~50% inhibition) in the amount of GH released in response to stimulation by 59 mM K+ (Fig. 4C). Overall, these findings are consistent with the idea that RalA plays a positive role in the exocytotic pathway of large dense core granules.



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 3.
Expression of the Ral-binding domain (RBD) of RalBP1 inhibits GH secretion from PC12 cells. PC12 cells were transfected (4 µg/well of each plasmid) with either pRK (empty vector), pRK-Myc-RBD, or pRK-MycRalBP1{Delta}RBD plasmids along with the plasmid (4 µg/well) encoding GH. A, 48 h after transfection, the expressed proteins were detected by Western blots using anti-Myc and anti-GH antibodies. B, transfected cells were washed and subsequently stimulated for 10 min with 59 mM K+ (closed bars) or incubated in calcium-free Locke's solution (open bars). Extracellular fluids were then collected, and GH present in solutions and in cells was estimated by radioimmunoassay. The total GH content per well was 5.81 ± 0.18 ng in control experiments with the empty pRK vector, 5.94 ± 0.25 ng in cells transfected with pRK-Myc-RBD, and 5.73 ± 0.19 ng in cells transfected with pRK-MycRalBP1{Delta}RBD. GH release is expressed as the percentage of total GH present in the cells before the 10-min stimulation period. Data are given as the mean values ± S.E. (n = 3). Similar results were obtained in three independent experiments performed with different cell cultures.

 
The implication of RalA in calcium-evoked exocytosis has been recently questioned based on the observation that wild-type RalA has no effect on calcium-dependent noradrenaline release when introduced into the cytosol of permeabilized PC12 cells (33). We therefore examined the effect of expressing wild-type RalA, the RalA(G23V) mutant defective in GTP hydrolysis and its corresponding dominant inactive mutant, RalA(G26A), preferentially binding GDP on GH secretion from PC12 cells. Consistent with the results of Wang et al. (33), overexpression of wild-type RalA did not modify GH secretion in response to high potassium (Fig. 5). However, expression of the constitutively active RalA(G23V) mutant increased GH release, whereas the dominant negative RalA(G26A) significantly decreased it (Fig. 5). These results emphasize the positive control that RalA is able to exert in calcium-regulated exocytosis.

RalA Binds to ARF6-activated PLD1 in Stimulated PC12 Cells—Because Ral proteins are known regulators of ARF-dependent PLD1 (8, 9), a protein that plays a key role in exocytosis in chromaffin and PC12 cells (35, 44), we investigated whether PLD1 might be an effector for RalA in the exocytotic pathway. Therefore, we first compared the distribution of RalA and PLD1 in resting and stimulated PC12 cells. In agreement with the localization of endogenous PLD1 (35, 44), GFP-PLD1 was found at the plasma membrane in both resting and stimulated cells (Fig. 6A). Immunostaining with anti-RalA antibodies revealed the close co-localization of RalA and GFP-PLD1 at the plasma membrane in resting cells (Fig. 6A). However, since endogenous RalA was barely detected in stimulated cells, it was not possible to compare its distribution with PLD1 under stimulatory conditions. When overexpressed, wild type RalA was also present at the plasma membrane in both resting (Fig. 7A) and K+-stimulated cells (Fig. 6A), where it was found to co-localize with GFP-PLD1 (Fig. 6A), in line with the idea that the two proteins might be able to interact in cells undergoing exocytosis.



View larger version (45K):
[in this window]
[in a new window]
  		FIG. 4.
Selective decrease of RalA expression by RNA interference inhibits PLD activation and GH secretion from PC12 cells. PC12 cells were transiently transfected with the pGHsuper vector (Control) or with the RalA-shRNA plasmid (RalA-siRNA) for 72 h. A, cells were lysed, and aliquots (25 µg of proteins) were used for electrophoresis and Western blot analysis using anti-GH, anti-RalA, and anti-RalB antibodies. B, transfected PC12 cells were fixed and stained with polyclonal anti-GH and monoclonal anti-RalA antibodies. Bar, 5 µm. C, PC12 cells transfected with pGHsuper (Control) or RalA-shRNA (RalA-siRNA) plasmids for 48 or 72 h were washed and subsequently incubated for 10 min in calcium-free Locke's solution (basal release) or stimulated for 10 min with 59 mM K+. Basal GH release (~5%) was unchanged and was subtracted from the GH release evoked by 59 mM K+ to obtain the net secretory response. Data are given as the mean values ± S.E. (n = 3). Similar results were obtained in two independent experiments performed with different cell cultures. D, cells transfected with pGHsuper (Control) or RalA-shRNA (RalA-siRNA) plasmids for 48 h were incubated 10 min in calcium-free Locke's solution (Resting) or stimulated for 10 min with 59 mM K+. Cells were then collected and assayed for PLD activity. Data are given as the mean values ± S.E. (n = 6). Similar results were obtained on four different cell preparations.

 



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 5.
Expression of RalA mutants alters GH secretion from PC12 cells. PC12 cells were transfected (4 µg/well of each plasmid) with either pRK (Empty vector), pRK-RalA(WT), pRK-RalA(G23V), or pRK-RalA(G26A) plasmids along with the plasmid (4 µg/well) encoding GH. 48 h after transfection, cells were incubated for 10 min in calcium-free Locke's solution (open bars) or stimulated for 10 min with 59 mM K+ (closed bars). GH present in extracellular fluids and in cells was estimated by radioimmunoassay. Approximately 5-10% of cells were successfully transfected with the GH-expressing vector as estimated by immunocytochemistry, and of these, more than 90% became co-transfected with the second plasmid. Data are given as the mean values ± S.E. (n = 3). Similar results were obtained in five independent experiments performed with different cell cultures.

 
Direct interaction of RalA with PLD1 was assessed by immunoprecipitation. We previously described that ARF6 is the upstream activator of the plasma membrane-bound PLD1 in the exocytotic pathway (36). ARF6 forms a complex with PLD1 in secretagogue-activated cells that could be co-precipitated from cells expressing HA-ARF6 using anti-HA antibodies (36). Using a similar approach, we examined whether RalA might be part of this complex. Therefore, PC12 cells expressing HA-ARF6 or the PLD1-nonresponsive HA-ARF6(N48I) mutant were stimulated with 59 mM K+ or maintained in resting conditions, collected, and processed for immunoprecipitation. As illustrated in Fig. 6B, precipitation of wild type HA-ARF6 co-precipitated endogenous PLD1 and RalA from lysates obtained from K+-stimulated cells but not from lysates from resting cells. Moreover, immunoprecipitation of the ARF6(N48I) mutant, which can bind to PLD1 but is unable to activate it (36), similarly co-precipitated PLD1 from lysates of K+-stimulated cells but was unable to pull down RalA (Fig. 6B). Taken together, these results indicate that RalA forms a specific complex with the ARF6-activated PLD1 at the plasma membrane in secretagogue-stimulated cells.

We previously described that in chromaffin cells, secretagogues stimulate an increase of PLD activity that was found to correlate in timing and calcium dependence with the exocytotic response (44). To unequivocally link RalA with this PLD activation, we measured PLD activity in control cells and in cells expressing RalA siRNA under resting and stimulated conditions. In agreement with our previous observations, we found that K+-evoked stimulation enhanced PLD activity in PC12 cells (Fig. 4D). However, this PLD activation was significantly reduced in cells expressing the RalA siRNA (Fig. 4D). From the data calculated from four independent experiments (six determinations/experiment) and taking into account that ~50% of the cells were transfected, we estimated that PLD activation was inhibited by 72% in cells with reduced endogenous RalA level. Thus, RalA belongs to the upstream activators that mediate PLD activation in secretagogue-stimulated cells.



View larger version (32K):
[in this window]
[in a new window]
  		FIG. 6.
RalA interacts with ARF6-activated PLD1 in stimulated PC12 cells. A, PC12 cells were transfected with the GFP-PLD1 expression plasmid alone or in combination with wild-type RalA. 48 h after transfection, cells were incubated for 10 min in Locke's solution (R) or stimulated with Locke containing 59 mM K+ (S). Cells were then fixed, and endogenous or overexpressed RalA was visualized by immunocytochemistry using anti-RalA antibodies and Alexa-555-conjugated secondary antibodies. In the merge images, the yellow-orange staining reveals areas where GFP-PLD1 and RalA co-localize. Masks represent the region of co-localization obtained by selecting the double-labeled pixels. Bars, 5 µm. B, PC12 cells expressing ARF6-HA or ARF6(N48I)-HA were incubated for 10 min in either Locke's solution (R) or in 59 mM K+ (S). Cells were scraped, and HA-tagged ARF6 proteins were immunoprecipitated. Samples were analyzed by electrophoresis and Western blotting using anti-ARF6, anti-PLD1, and anti-RalA antibodies. Similar observations were obtained from two different cell preparations.

 
PLD1 Is a Molecular Partner for RalA in the Exocytotic Machinery—To further probe the idea that PLD1 is an effector by which RalA regulates the exocytotic process, we expressed in PC12 cells various GTP-bound RalA(G23V) mutants previously shown to be selectively uncoupled from known RalA effectors, namely RalA(G23V,T46A) (unable to associate with RalBP1) (12), RalA(G23V,D49E) (unable to interact with the exocyst subunit Sec5) (15), and {Delta}Nt-RalA(G23V) (deleted of the amino-terminal 11 amino acids, which are required for association of Ral with PLD) (8). Fig. 7A illustrates the intracellular distribution of these various RalA proteins. Double staining with anti-SNAP-25 antibodies confirmed that the mutants retained their ability to associate with the plasma membrane in resting (Fig. 7A) and stimulated PC12 cells (data not shown).



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 7.
Effect of various RalA mutated proteins on secretagogue-evoked GH release from PC12 cells. A, PC12 cells expressing the indicated RalA mutants were fixed and stained with anti-RalA and anti-SNAP25 antibodies visualized with Alexa-555- and Alexa-488-conjugated secondary antibodies. Bars, 5 µm. B, PC12 cells cotransfected with GH and the indicated RalA constructs were incubated for 10 min in calcium-free Locke's solution (Resting) or stimulated for 10 min with 59 mM K+ (Stimulated). GH release is expressed as the percentage of total GH present in cells before stimulation. Data are given as the mean values ± S.E. (n = 3). *, p < 0.05 when tested by Student's t test. Similar results were obtained in three independent experiments performed on different cell cultures.

 
The effect of the RalA variants on K+-evoked GH secretion is shown in Fig. 7B. RalA(G23V,T46A) uncoupled from RalBP1 retained a stimulatory activity comparable with the active RalA(G23V), excluding RalBP1 as an effector of RalA in the exocytotic process. Accordingly, RalBP1 has been described as a direct effector of Ral-mediated regulation of receptor endocytosis (23, 45). RalA(G23V,D49E) was also able to stimulate the exocytotic response, albeit slightly less efficiently than RalA(G23V). In contrast, {Delta}Nt-RalA(G23V) uncoupled from PLD1 was unable to retain a significant stimulatory activity (Fig. 7B). These data are consistent with the proposal that PLD1 is a major partner for RalA in the exocytotic process of large dense core secretory granules.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Ral GTPases display two properties that could potentially serve to regulate exocytosis in neurosecretory cells; they interact with the exocyst (Sec6/8 complex), and they stimulate PLD activity. The exocyst complex comprises eight proteins originally identified in the budding yeast, where they have been shown to be essential for exocytosis (17, 46). Mammalian counterparts for each of these proteins have been identified (47), and it has been suggested that the function of the exocyst complex is to mark the plasma membrane as a delivery site for exocytotic vesicles (27, 48). Thus, Ral may participate in regulated exocytosis by controlling the exocyst assembly (26) and tether vesicles in proximity to the plasma membrane-bound SNAREs involved in docking and fusion. RalA has also been shown to interact directly with PLD1 and to enhance ARF-stimulated PLD1 activity (8, 9). PLD1 generates phosphatidic acid, a multifunctional lipid that has been involved in vesicular trafficking by altering membrane curvature and favoring fusion, serving as a protein attachment site, activating selected enzymes, or representing the starting material for the production of additional signaling lipids. We previously demonstrated that PLD1 constitutes a critical factor for regulated exocytosis in neuroendocrine cells (35) and neurons (49), electing PLD1 as another potential target by which Ral proteins may control the exocytotic machinery.

In this report, we present data indicating that RalA is found on the plasma membrane in chromaffin and PC12 cells, where it co-localizes with PLD1 upon cell stimulation. Co-precipitation experiments revealed that RalA interacts directly with ARF6-activated PLD1 in stimulated but not in resting cells, suggesting that RalA may be functionally linked to the plasma membrane-bound PLD1 in the course of exocytosis. Transfection experiments with RalA mutants or silencing of the RalA gene by an RNAi strategy confirm the involvement of RalA in the exocytotic process. Expression of the constitutively active RalA(G23V) strongly enhanced GH secretion from PC12 cells. Conversely, reduction of endogenous RalA inhibited secretion, favoring a positive role for RalA in large dense core granule exocytosis. Consistent with these results, active RalA has been recently reported to enhance basolateral membrane delivery and secretion in epithelial cells (25). How does GTP-loaded RalA facilitate exocytosis in PC12 cells? We found that a RalA(G23V) mutant truncated in the amino-terminal region and unable to interact with PLD1 completely lost its ability to enhance secretagogue-evoked GH release. Together with the observations that RalA interacts with ARF6 and PLD1 at the plasma membrane in stimulated cells and mediates PLD activation upon secretagogue-evoked stimulation, these results suggest that stimulation of the ARF6-dependent PLD1 is the major function RalA undertakes in regulated exocytosis in neuroendocrine cells. Hence, despite the presence of Sec6 on large dense core secretory granules (50), there is still no direct evidence for a function of the exocyst in regulated exocytosis in neuroendocrine cells. Moreover, exocyst subunits are down-regulated in mature synapses (28), an observation that has led to the idea that the complex participates in formation of synapses rather than in synaptic vesicle release in established synapses. Accordingly, in Drosophila with mutations in a central structural component of the complex, it was found recently that defects in the exocyst inhibited neurite outgrowth, but release of neurotransmitter at the synapse persisted (51). The present results indicating that PLD1 is a major molecular partner for RalA in the exocytotic pathway in neuroendocrine cells raise also the question of the actual implication of the exocyst in dense core granule exocytosis.

In chromaffin and PC12 cells, PLD1 is found at the plasma membrane and is activated by granule-associated ARF6 following secretagogue-induced targeting and docking of granules onto the plasma membrane (35, 36). Functional studies based on the expression or microinjection of various PLD1 mutants confirmed that ARF6-regulated PLD1 operates at a step that lies subsequent to the cytoskeleton-mediated recruitment of secretory granules to the exocytotic sites at the plasma membrane (35). Thus, through the stimulation of PLD1, RalA might enhance neuroendocrine secretion by influencing some late postdocking events in the exocytotic pathway. In neurons, however, RalA has been reported to control the refilling of the readily releasable pool of synaptic vesicles docked at the plasma membrane, most likely by modulating some synapsin/cytoskeleton-mediated events (32). Thus, despite the similarities between the exocytotic machinery underlying hormone and neurotransmitter release, RalA seems to play a distinct function, perhaps related to the observation that it is associated with synaptic vesicles in neurons (26, 29, 30, 52) but found on the plasma membrane in neuroendocrine cells. On the other hand, PLD1 plays also a role in late stages of neurotransmitter release, most likely by controlling the fusogenic status of presynaptic release sites (49). Whether RalA might be able to modulate this PLD1 activity in neurons has not yet been investigated.

The involvement of PLD1 in a late postdocking step of exocytosis implies a precise regulation of its enzymatic activity. This may be achieved through a tight spatial and temporal regulation of the granule-bound ARF6 activation/inactivation cycle. Hence, ARNO, the guanine nucleotide exchange factor controlling the activity of ARF6 (36, 53), activates ARF6 only after recruitment and docking of granules to the plasma membrane (36). However, exocytosis in neuroendocrine cells is above all a calcium-regulated event, and additional mechanisms are likely to occur at the plasma membrane to link ARF6-dependent PLD1 to variations in cytosolic calcium. With this in mind, it is interesting to recall that RalA is activated by cytosolic calcium (7). Accordingly, we show here that RalA activation occurs in response to membrane depolarization, which directly triggers calcium influx through voltage-gated calcium channels. Moreover, RalA contains a calmodulin-binding site at its C terminus, and Ca2+-calmodulin binding stimulates GTP binding to RalA, suggesting that calmodulin is an RalA activator (54, 55). Calmodulin is also an established regulator of exocytosis (56) that has been implicated in a late role in secretory granule release by signaling through membrane-attached molecules to increase exocytosis (57, 58). The possibility that RalA represents an additional checkpoint that integrates calcium/calmodulin signals to PLD1 and its lipid-modifying activity at the sites of exocytosis is an attractive line of future investigation.


   FOOTNOTES
 
* This work was supported by Association de la Recherche sur le Cancer Grant 3208 (to M.-F. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

|| To whom correspondence should be addressed: CNRS UPR-2356, 5 rue Blaise Pascal, 67084 Strasbourg cedex, France. Tel.: 33-3-88-45-67-13; Fax: 33-3-88-60-16-64; E-mail: bader{at}neurochem.u-strasbg.fr.

1 The abbreviations used are: PLD, phospholipase D; siRNA, small interference RNA; shRNA, small hairpin RNA; GH, growth hormone. Back


   ACKNOWLEDGMENTS
 
We thank Dr. A. F. Parlow and the NIDDK National Hormone and Pituitary Program for generously providing polyclonal anti-GH antibodies. We are grateful to Dr. S. Gasman for helpful comments on the manuscript and to V. Calco and T. Thahouly for technical assistance. We acknowledge the confocal microscopy facilities of Plate-forme Imagerie In Vitro of IFR 37.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Chardin, P., and Tavitian, A. (1989) Nucleic Acids Res. 17, 4380[Free Full Text]
  2. Bhullar, R. P., and Yang, S. (1998) Mol. Cell Biochem. 179, 49-55[CrossRef][Medline] [Order article via Infotrieve]
  3. Feig, L. A. (2003) Trends Cell Biol. 13, 419-425[CrossRef][Medline] [Order article via Infotrieve]
  4. Bos, J. L. (1998) EMBO J. 17, 6776-6782[CrossRef][Medline] [Order article via Infotrieve]
  5. Reuther, G. W., and Der, C. J. (2000) Curr. Opin. Cell. Biol. 12, 157-165[CrossRef][Medline] [Order article via Infotrieve]
  6. Hofer, F., Berdeaux, R., and Martin, G. S. (1998) Curr. Biol. 8, 839-842[CrossRef][Medline] [Order article via Infotrieve]
  7. Wolthuis, R. M., Franke, B., van Triest, M., Bauer, B., Cool, R. H., Camonis, J. H., Akkerman, J. W., and Bos, J. L. (1998) Mol. Cell. Biol. 18, 2486-2491[Abstract/Free Full Text]
  8. Luo, J. Q., Liu, X., Frankel, P., Rotunda, T., Ramos, M., Flom, J., Jiang, H., Feig, L. A., Morris, A. J., Kahn, R. A., and Foster, D. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 3632-3637[Abstract/Free Full Text]
  9. Kim, J. H., Lee, S. D., Han, J. M., Lee, T. G., Kim, Y., Park, J. B., Lambeth, J. D., Suh, P. G., and Ryu, S. H. (1998) FEBS Lett. 430, 231-235[CrossRef][Medline] [Order article via Infotrieve]
  10. Cantor, S. B., Urano, T., and Feig, L. A. (1995) Mol. Cell. Biol. 15, 4578-4584[Abstract]
  11. Park, S. H., and Weiberg, R. A. (1995) Oncogene 11, 2349-2355[Medline] [Order article via Infotrieve]
  12. Jullien-Flores, V., Dorseuil, O., Romero, F., Letourneur, F., Saragosti, S., Berger, R., Tavitian, A., Gacon, G., and Camonis, J. H. (1995) J. Biol. Chem. 270, 22473-22477[Abstract/Free Full Text]
  13. Ohta, Y., Suzuki, N., Nakamura, S., Hartwig, J. H., and Stossel, T. P. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 2122-2128[Abstract/Free Full Text]
  14. Brymora, A., Valova, V. A., Larsen, M. R., Roufogalis, B. D., and Robinson, P. J. (2001) J. Biol. Chem. 276, 29792-29797[Abstract/Free Full Text]
  15. Moskalenko, S., Henry, D. O., Rosse, C., Mirey, G., Camonis, J. H., and White, M. A. (2002) Nat. Cell Biol. 4, 66-72[CrossRef][Medline] [Order article via Infotrieve]
  16. Sugihara, K., Asano, S., Tanaka, K., Iwamatsu, A., Okawa, K., and Ohta, Y. (2002) Nat. Cell Biol. 4, 73-78[CrossRef][Medline] [Order article via Infotrieve]
  17. Terbush, D. R., Maurice, T., Roth, D., and Novick, P. (1996) EMBO J. 15, 6483-6494[Medline] [Order article via Infotrieve]
  18. Hsu, S. C., Ting, A. E., Hazuka, C. D., Davanger, S., Kenny, J. W., Kee, Y., and Scheller, R. H. (1996) Neuron 17, 1209-1219[CrossRef][Medline] [Order article via Infotrieve]
  19. Lipschutz, J. H., and Mostov, K. E. (2002) Curr. Biol. 12, R212-R214[CrossRef][Medline] [Order article via Infotrieve]
  20. Yamaguchi, A., Urano, T., Goi, T., and Feig, L. A. (1997) J. Biol. Chem. 272, 31230-31234[Abstract/Free Full Text]
  21. Ikeda, M., Ishida, O., Hinoi, T., Kishida, S., and Kikuchi, A. (1998) J. Biol. Chem. 273, 814-821[Abstract/Free Full Text]
  22. Santolini, E., Salcini, A. E., Kay, B. K., Yamabhai, M., and Di Fiore, P. P. (1999) Exp. Cell Res. 253, 186-209[CrossRef][Medline] [Order article via Infotrieve]
  23. Jullien-Flores, V., Mahe, Y., Mirey, G., Leprince, C., Meunier-Bisceuil, B., Sorkin, A., and Camonis, J. H. (2000) J. Cell Sci. 113, 2837-2844[Abstract]
  24. Shen, Y., Xu, L., and Foster, D. A. (2001) Mol. Cell. Biol. 21, 595-602[Abstract/Free Full Text]
  25. Shipitsin, M., and Feig, L. A. (2004) Mol. Cell. Biol. 24, 5746-5756[Abstract/Free Full Text]
  26. Moskalenko, S., Tong, C., Rosse, C., Camonis, J., and White, M. A. (2003) J. Biol. Chem. 278, 51743-51748[Abstract/Free Full Text]
  27. Grindstaff, K. K., Yeaman, C., Anandasabapathy, N., Hsu, S. C., Rodriguez-Boulan, E., Scheller, R. H., and Nelson, W. J. (1998) Cell 93, 731-740[CrossRef][Medline] [Order article via Infotrieve]
  28. Hazuka, C. D., Foletti, D. L., Hsu, S. C., Kee, Y., Hopf, F. W., and Scheller, R. H. (1999) J. Neurosci. 19, 1324-1334[Abstract/Free Full Text]
  29. Ngsee, J. K., Elferink, L. A., and Scheller, R. H. (1991) J. Biol. Chem. 266, 2675-2680[Abstract/Free Full Text]
  30. Bielinski, D. F., Pyun, H. Y., Linko-Stentz, K., Macara, I. G., and Fine, R. E. (1993) Biochim. Biophys. Acta 1151, 246-256[Medline] [Order article via Infotrieve]
  31. Mark, B. L., Jilkina, O., and Bhullar, R. P. (1996) Biochim. Biophys. Res. Commun. 225, 40-46[CrossRef][Medline] [Order article via Infotrieve]
  32. Polzin, A., Shipitsin, M., Goi, T., Feig, L. A., and Turner, T. J. (2002) Mol. Cell. Biol. 22, 1714-1722[Abstract/Free Full Text]
  33. Wang, L., Li, G., and Sugita, S. (2004) J. Biol. Chem. 279, 19875-19881[Abstract/Free Full Text]
  34. Gasman, S., Chasserot-Golaz, S., Popoff, M. R., Aunis, D., and Bader, M. F. (1999) J. Cell Sci. 112, 4763-4771[Abstract]
  35. Vitale, N., Caumont, A. S., Chasserot-Golaz, S., Du, G., Wu, S., Sciorra, V. A., Morris, A. J., Frohman, M. A., and Bader, M. F. (2001) EMBO J. 20, 2424-2434[CrossRef][Medline] [Order article via Infotrieve]
  36. Vitale, N., Chasserot-Golaz, S., Bailly, Y., Morinaga, N., Frohman, M. A., and Bader, M. F. (2002) J. Cell Biol. 159, 79-89[Abstract/Free Full Text]
  37. Brummelkamp, T. R., Bernards, R., and Agami, R. (2002) Science 296, 550-553[Abstract/Free Full Text]
  38. Waselle, L., Coppola, T., Fukuda, M., Iezzi, M., El-Amraoui, A., Petit, C., and Regazzi, R. (2003) Mol. Biol. Cell 10, 4103-4113
  39. Bader, M. F., Thiersé, D., Aunis, D., Ahnert-Hilger, G., and Gratzl, M. (1986) J. Biol. Chem. 261, 5777-5783[Abstract/Free Full Text]
  40. Chasserot-Golaz, S., Vitale, N., Sagot, I., Delouche, B., Dirrig, S., Pradel, L. A., Henry, J. P., Aunis, D., and Bader, M. F. (1996) J. Cell Biol. 133, 1217-1236[Abstract/Free Full Text]
  41. Ehrhart, M., Grube, D., Bader, M. F., Aunis, D., and Gratzl, M. (1986) J. Histochem. Cytochem. 34, 1673-1682[Abstract]
  42. Hammond, S. M., Caudy, A. A., and Hannon, G. J. (2001) Nat. Rev. Genet. 2, 110-119[CrossRef][Medline] [Order article via Infotrieve]
  43. Elbashir, S. M., Lendeckel, W., and Tuschl, T. (2001) Genes Dev. 15, 188-200[Abstract/Free Full Text]
  44. Caumont, A. S., Galas, M. C., Vitale, N., Aunis, D., and Bader, M. F. (1998) J. Biol. Chem. 273, 1373-1379[Abstract/Free Full Text]
  45. Nakashima, S., Morinaka, K., Koyama, S., Ikeda, M., Kishida, M., Okawa, K., Iwamatsu, A., Kishida, S., and Kikuchi, A. (1999) EMBO J. 18, 3629-3642[CrossRef][Medline] [Order article via Infotrieve]
  46. Hsu, S. C., Hazuka, C. D., Foletti, D. L., and Scheller, R. H. (1999) Trends Cell Biol. 9, 150-153[CrossRef][Medline] [Order article via Infotrieve]
  47. Kee, Y., Yoo, J. S., Hazuka, C. D., Peterson, K. E., Hsu, S. C., and Scheller, R. H. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 14438-14443[Abstract/Free Full Text]
  48. Inoue, M., Chang, L., Hwang, J., Chiang, S. H., and Saltiel, A. R. (2003) Nature 422, 629-633[CrossRef][Medline] [Order article via Infotrieve]
  49. Humeau, Y., Vitale, N., Chasserot-Golaz, S., Dupont, J. L., Du, G., Frohman, M. A., Bader, M. F., and Poulain, B. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 15300-15305[Abstract/Free Full Text]
  50. Vik-Mo, E. O., Oltedal, L., Hoivik, E. A., Kleivdal, H., Eidet, J., and Davanger, S. (2003) Neuroscience 119, 73-85[CrossRef][Medline] [Order article via Infotrieve]
  51. Murthy, M., Garza, D., Scheller, R. H., and Schwartz, T. L. (2003) Neuron 37, 433-447[CrossRef][Medline] [Order article via Infotrieve]
  52. Volknandt, W., Pevsner, J., Elferink, L. A., and Scheller, R. H. (1993) FEBS Lett. 317, 53-56[CrossRef][Medline] [Order article via Infotrieve]
  53. Caumont, A. S., Vitale, N., Gensse, M., Galas, M. C., Casanova, J. E., and Bader, M. F. (2000) J. Biol. Chem. 275, 15637-15644[Abstract/Free Full Text]
  54. Wang, K. L., and Roufogalis, B. D. (1999) J. Biol. Chem. 274, 14525-14528[Abstract/Free Full Text]
  55. Clough, R. R., Sidhu, R. S., and Bhullar, R. P. (2002) J. Biol. Chem. 277, 28972-28980[Abstract/Free Full Text]
  56. Burgoyne, R. D., and Clague, M. J. (2003) Biochim. Biophys. Acta 1641, 137-143[Medline] [Order article via Infotrieve]
  57. Chamberlain, L. H., Roth, D., Morgan, A., and Burgoyne, R. D. (1995) J. Cell Biol. 130, 1063-1070[Abstract/Free Full Text]
  58. Chen, Y. A., Duvvuri, V., Schulman, H., and Scheller, R. H. (1999) J. Biol. Chem. 274, 26469-26476[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
M. G. Rondaij, R. Bierings, E. L. van Agtmaal, K. A. Gijzen, E. Sellink, A. Kragt, S. S. G. Ferguson, K. Mertens, M. J. Hannah, J. A. van Mourik, et al.
Guanine exchange factor RalGDS mediates exocytosis of Weibel-Palade bodies from endothelial cells
Blood, July 1, 2008; 112(1): 56 - 63.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. A. Lopez, E. P. Kwan, L. Xie, Y. He, D. E. James, and H. Y. Gaisano
The RalA GTPase Is a Central Regulator of Insulin Exocytosis from Pancreatic Islet Beta Cells
J. Biol. Chem., June 27, 2008; 283(26): 17939 - 17945.
[Abstract] [Full Text] [PDF]